Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

Medical pioneers Hims & Hers Health HIMS and Novo Nordisk NVO are making headlines this week after announcing a partnership to expand obesity care in the telehealth space. The long-term ...

As of 11:20 a.m. ET, Hims & Hers stock is surging to 11.2% and beyond, whereas both Eli Lilly and Novo Nordisk stocks are down 3.2%. Hims & Hers reported a surge in sales in the first quarter of ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

Credit: Novo Nordisk. Self-paying patients will now be able to access NovoCare Pharmacy directly through the telehealth ...